STRATEGIES FOR STUDYING BRAIN DISORDERS

Vol.4 Interactive Monoaminergic Disorders

Vol.4 Interactive Monoaminergic Disorders

Editors:Tomás Palomo, Richard J. Beninger, Trevor Archer

January 1999

Publisher: Editorial Síntesis, Vallehermoso, 34, 28015 MADRID

ISBN: 84-7738-623-4

Pages: 797

Congresos

Interactive Monoaminergic Basis of Brain Disorders

Mojácar (Almería)

October 8 - 12 1997

The content of this congress, together with other contributions on the topic, are collected in vol. 4 of the series "Strategies for studying brain disorders".

PROGRAMME

  • Tomás Palomo and Trevor Archer.
    The interactive essence underlying the dopamine disease states.

S1. DISORDERS OF ANXIETY, DEPRESSION AND SOCIAL BEHAVIOUR

  • Gerald Curzon, U.K.
    Neurochemistry and drug treatment of depression and its implications.
  • R. John Rodgers, U.K.
    Serotonin receptors and possible interactions in anxiety.
  • Peter Nordström, Sweden.
    Survival analysis and psychobiology of suicide risk.
  • Victor Pérez-Sola, Spain.
    Receptor interactions in clinical delayed response.
  • Herman Van Praag, The Netherlands.
    Is depression a mood disorder?.
  • Philipp Cowen, U.K.
    Serotonin in the pathophysiology of depression and the action of antidepressant drugs.

S2. SUBSTANCE ABUSE AND RELATED DISORDERS

  • Jack Henningfield, USA.
    Pathophysiology of nicotine dependence: Implications for the regulation of cigarettes and treatment of nicotine dependence.
  • Robert Balster, USA.
    Interactions among monoaminergic and glutamatergic systems in the neural basis of substance abuse.
  • Miguel Casas-Brugé, Spain.
    Effects of Naltrexone on the expression of environmental conditioned self-injurious behaviour in rats: Relevance in drug addictions.
  • Michael W. Oglesby, USA.
    Tolerance to the subjective effects of CNRS stimulants.
  • Jorgen Engel, Sweden.
    Neurochemical and behavioural studies on ethanol and nicotine interactions.

S3. SCHIZO-PSYCHOTIC DISORDERS

  • Bita Moghaddam, USA.
    Neurochemical and behavioural studies of dopamine-glutamate interactions.
  • Mark Geyer, USA.
    Multiple Transmitters Modulate Prepulse Inhibition: Relevance to Schizophrenia.
  • Stevin H. Zorn, USA.
    Pharmacological and Neurochemical Studies with the new antipsychotic ziprasidone.
  • Nicholas A. Moore, UK.
    Expected neuropharmacological profiles of novel antipsychotic agents.
  • Torgny Svensson, Sweden.
    Stabilization of mesocorticolimbic dopamine systems in psicosis by concomitant 5-HT2A and α1 receptor blockade.
  • Victor Peralta, Spain.
    Clinical models of squizophrenia: A critical approach to competing conceptions.
  • Anna-Lena Nordström, Sweden.
    Neuroimaging profiles of D2-5HT2 receptors.

S4. MOVEMENT DISORDERS

  • Ulrich Ebert, Germany.
    Monoamine interactions in animal models of epilepsy.
  • Trevor Archer, Sweden.
    Functional effects of acute and chronic L-dopa upon hypokinesive MPTP mice: Glutamate antagonists and inhibitors of MAO/COMT.
  • Pierre Sokoloff, France.
    Functional and therapeutic implications of D1/D3 receptor interactions.
  • Werner J. Schmidt, Germany.
    Monoamine-glutamate interactions in motor activity and learning.
  • Erik Claveria, Spain.
    Treatment profiles of compounds useful for the movement disorders.
  • Thomas N. Chase, USA.
    Striatal dopaminergic-glutamatergic interactions: Contribution to response alterations to levodopa in advanced Parkinson’s disease.

S5. NEUROPHARMACOLOGY OF DRUG-RECEPTOR ACTIONS.

  • Richard J. Beninger, Canada.
    Dopamine-second messenger interactions in reward-related learning.
  • David Jackson, Sweden.
    Nitric oxide synthase (NOS), phencyclide (PCP)-induced behaviours and schizophrenia
  • David Sanger, France.
    Using drugs discrimination in rats to investigate the pharmacology of Dopamine D3 receptors.
  • Jorge Manzanares, Spain.
    New agonists and antagonist of 5-HT1A receptor as potential tools in neuropsychiatric disorders.
  • Robert Dantzer, France.
    Neuroimmune interactions and brain disorders.

S6. GENERAL CONSIDERATIONS DRUG-RECEPTOR INTERACTIONS IN BRAIN DISORDERS

  • Alain Schotte, Belgium.
    Functional correlates of neurotransmitter receptor occupancy by antipsychotic drugs in the rat brain: the induction of neurotensin mRNA.
  • Ivan Izquierdo, Brasil.
    Brain neurotransmitter interactions: The model case of memory processing.
  • Peter Kalivas, USA.
    Drug-and stress-induced psychotic behaviours implying multisystems.
  • Anna Sluzewska, Poland.
    Immunologic factors in major depression and treatment resistant depression.
  • Tomás Palomo, Spain.
    Interactive Monoaminergic Basis of Brain Disorders.

Fundación Cerebro y Mente
c/ General Oraa, 47 - 1º E 28006 Madrid, España
Telf: +34 91 561 1267 Fax: +34 91 564 1817
http://www.cermente.com

Resolución mínima: 1024 x 768. Navegadores recomendados: Google Chrome / Firefox 3.5+ / Internet Explorer 9.0+ / Opera 9.0+ / Safari 3.0+